New study below.
We are 30+ years into the Lupron era, but diethylstilbestrol [DES] was used for about 45 years before that & shouldn't be entirely ignored.
DES is a synthetic estrogen. The male response to high amounts of estrogen is reduced testosterone production (the presumed source of the estrogen, via aromatization). However, in a very small minority of men, DES does not lower T, & yet does lower PSA, indicating that it has anti-PCa properties unrelated to castration.
In fact, some men on Lupron who become "castrate-resistant", have a response to DES:
(2014 - Israel [2]) "Patients treated with DES during the castration-resistant phase following the failure of prior treatment with LH-RH analogs during the castration-sensitive phase were retrieved from a prostate cancer database of our institution. Patients were treated with a daily dose of DES of 1-4 mg (mean, 2.6 mg) and anticoagulants for thromboembolic prophylaxis until disease progression."
"Forty-three DES-treated CRPC patients were found in our database through July 2011. The median age was 66 years. Sixty-three percent of the patients achieved a ≥50% decline in their serum PSA levels during DES therapy. Median TDP {time to disease progression} was 20.4 months for LH-RH analog treatment in the castration-sensitive phase, and 7.1 months for DES treatment in the castration-resistant phase. Durable responses (>1 year) were observed in 31% of the patients. Median overall survival was 57 months from the start of the DES therapy."
Although DES production in the U.S. ended twenty years ago, it can be obtained from compounding pharmacies.
The new Spanish-Portuguese study found an interesting effect on HIF-1α.
When tumors outgrow their blood supply, the drop in oxygen (hypoxia) triggers HIF-1α (hypoxia-inducible factor 1α). This is bad news, because HIF is the ultimate survival response. Therapies stop working, new blood vessels form, etc.
"Oxygen deprivation prompted a number of changes in intracellular composition and metabolic activity, mainly reflecting upregulated glycolysis, amino acid catabolism and other compensatory mechanisms used by hypoxic cells to deal with oxidative imbalance and energy deficit."
"Cell treatment with a non-cytotoxic concentration of DES, under hypoxia, triggered significant changes in 17 metabolites. Among these, lactate, phosphocreatine and reduced glutathione, whose levels showed opposite variations in hypoxic and drug-treated cells, emerged as possible markers of DES-induced HIF-1α inhibition."
"Overall, this study has revealed a number of unanticipated metabolic changes that inform on DES ... direct cellular effects ..."
{Incidentally, my approach to HIF-1α inhibition is a daily nitroglycerine patch, which improves blood supply to tumors.
-Patrick